Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells

Journal of Cellular Biochemistry

Volumn 104, Issue 4, 2008, Pages 1452-1464

  Cross, N A ^a   Waterman, E A ^a   Jokonya, N ^a   Fowles, A ^a   Buckle, C H ^a   Phillips, J ^a   Holen, I ^a   Hamdy, F C ^a   Eaton, C L ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Apoptosis; Bone metastasis; Clonal variation; Osteolytic; Osteoprotegerin; Prostate cancer; RANKL; TRAIL

Indexed keywords

OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CLONE; CLONAL VARIATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CLONE CELLS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION; HUMANS; MALE; OSTEOPROTEGERIN; PHENOTYPE; PROSTATIC NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 46949090145     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21721     Document Type: Article

References (33)

1. Barnes LM, Moy N, Dickson AJ. 2006. Phenotypic variation during cloning procedures: Analysis of the growth behaviour of clonal cell lines. Biotechnol Bioeng 94:530-537.
2. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R. 2003. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 34:263-264.
3. Brown JM, Vessella RL, Kostenuik PJ, Dunstan CR, Lange PH, Corey E. 2001. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res 7:2977-2983.
4. Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL. 2002. Establishment and characterization of osseous prostate cancer models: Intra-tibial injection of human prostate cancer cells. Prostate 52:20-33.
5. Corey E, Brown LG, Kiefer JA, Quinn JE, Pitts TE, Blair JM, Vessella RL. 2005. Osteoprotegerin in prostate cancer bone metastasis. Cancer Res 65:1710-1718.
6. Cross NA, Rennie IG, Murray AK, Sisley K. 2005. The identification of chromosome abnormalities associated with the invasive phenotype of uveal melanoma in vitro. Clin Exp Metastasis 22:107-113.
7. Eaton CL, Wells JM, Holen I, Croucher PI, Hamdy FC. 2004. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. Prostate 59:304-310.
8. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR. 1998. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273:14363-14367.
9. Fish RJ, Kruithof EK. 2004. Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors. BMC Mol Biol 5:9.
10. Fisher JL, Thomas-Mudge RJ, Elliott J, Hards DK, Sims NA, Slavin J, Martin TJ, Gillespie MT. 2006. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res 66:3620-3628.
11. Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET. 2005. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 65:7554-7560.
12. Hausser HJ, Brenner RE. 2005. Phenotypic instability of Saos-2 cells in long-term culture. Biochem Biophys Res Commun 333:216-222.
13. Holen I, Croucher PI, Hamdy FC, Eaton CL. 2002. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 62:1619-1623.
14. Holen I, Cross SS, Neville-Webbe HL, Cross NA, Balasubramanian SP, Croucher PI, Evans CA, Lippitt JM, Coleman RE, Eaton CL. 2005. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo-A role in tumour cell survival? Breast Cancer Res Treat 92:207-215.
15. Jung K, Lein M, von Hosslin K, Brux B, Schnorr D, Loening SA, Sinha P. 2001. Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer. Clin Chem 47:2061-2063.
16. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P, Hooley J, Sherwood S, Pai R, Leung S, Khan L, Gliniak B, Bussiere J, Smith CA, Strom SS, Kelley S, Fox JA, Thomas D, Ashkenazi A. 2001. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7:383-385.
17. Locke M, Heywood M, Fawell S, Mackenzie IC. 2005. Retention of intrinsic stem cell hierarchies in carcinoma-derived cell lines. Cancer Res 65:8944-8950.
18. Naumann U, Wick W, Beschorner R, Meyermann R, Weller M. 2004. Expression and functional activity of osteoprotegerin in human malignant gliomas. Acta Neuropathol (Berl) 107:17-22.
19. Neville-Webbe HL, Cross NA, Eaton CL, Nyambo R, Evans CA, Coleman RE, Holen I. 2004. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat 86:269-279.
20. Nugoli M, Chuchana P, Vendrell J, Orsetti B, Ursule L, Nguyen C, Birnbaum D, Douzery EJ, Cohen P, Theillet C. 2003. Genetic variability in MCF-7 sublines: Evidence of rapid genomic and RNA expression profile modifications. BMC Cancer 3:13.
21. Nyambo R, Cross N, Lippitt J, Holen I, Bryden G, Hamdy FC, Eaton CL. 2004. Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis. J Bone Miner Res 19:1712-1721.
22. Oh MK, Scoles DR, Haipek C, Strand AD, Gutmann DH, Olson JM, Pulst SM. 2003. Genetic heterogeneity of stably transfected cell lines revealed by expression profiling with oligonucleotide microarrays. J Cell Biochem 90:1068-1078.
23. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM. 1997a. The receptor for the cytotoxic ligand TRAIL. Science 276:111-113.
24. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. 1997b. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277:815-818.
25. Pebernard S, Iggo RD. 2004. Determinants of interferon-stimulated gene induction by RNAi vectors. Differentiation 72:103-111.
26. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. 1996. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271:12687-12690.
27. Rabin N, Kyriakou C, Coulton L, Gallagher OM, Buckle C, Benjamin R, Singh N, Gassford J, Otsuki T, Nathwani AC, Croucher PI, Yong KL. 2007. A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer. Leukemia 21:2181-2191.
28. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. 1997. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818-821.
29. Shipman CM, Croucher PI. 2003. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 63:912-916.
30. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. 1997. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309-319.
31. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673-682.
32. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET. 2001. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107:1235-1244.
33. Zhang X, Jin TG, Yang H, DeWoIf WC, Khosravi-Far R, Olumi AF. 2004. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res 64:7086-7091.